Aeolus Pharmaceuticals, Inc.
AOLS
$0.0001
$0.000.00%
| 06/30/2017 | 03/31/2017 | 12/31/2016 | 09/30/2016 | 06/30/2016 | |
|---|---|---|---|---|---|
| Revenue | -98.03% | -77.17% | -72.79% | -41.54% | 947.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.03% | -77.17% | -72.79% | -41.54% | 947.62% |
| Cost of Revenue | -52.99% | 18.56% | -0.61% | 1.44% | 236.06% |
| Gross Profit | -68.85% | -826.56% | -117.11% | -1,116.67% | -18.45% |
| SG&A Expenses | -14.49% | -17.75% | 21.39% | 47.73% | 8.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.21% | -2.51% | 11.11% | 14.86% | 80.87% |
| Operating Income | -8.83% | -64.55% | -45.32% | -136.81% | -11.22% |
| Income Before Tax | -8.83% | -64.55% | -5.23% | -135.71% | -11.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.83% | -64.55% | -5.23% | -135.71% | -11.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.83% | -64.55% | -5.23% | -135.71% | -11.22% |
| EBIT | -8.83% | -64.55% | -45.32% | -136.81% | -11.22% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -6.90% | 59.28% | 38.79% | -109.38% | 0.00% |
| Normalized Basic EPS | -8.33% | -65.38% | 2.17% | -110.00% | 0.00% |
| EPS Diluted | 0.00% | 50.00% | 13.79% | -212.50% | 0.00% |
| Normalized Diluted EPS | -8.33% | -65.38% | 2.17% | -110.00% | 0.00% |
| Average Basic Shares Outstanding | 0.29% | 0.35% | 9.07% | 11.90% | 11.59% |
| Average Diluted Shares Outstanding | 0.29% | 0.35% | 9.07% | 11.90% | 11.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
